BCMIO
MYGN icon

Beacon Capital Management Inc (Ohio)’s Myriad Genetics MYGN Stock Holding History

Beacon Capital Management Inc (Ohio)’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3
Closed – – 159
2017
Q1 		$0 Buy
+3
New +$53 ﹤0.01% 163

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Beacon Capital Management Inc (Ohio)'s MYGN Position: Q2 2017 in Review

Beacon Capital Management Inc (Ohio) sold out of Myriad Genetics (MYGN) in Q2 2017, closing a stake of 3 shares.

Beacon Capital Management Inc (Ohio) first reported a position in MYGN in Q1 2017 and held it in 1 quarter. The position peaked at $0 in Q1 2017. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

  • Beacon Capital Management Inc (Ohio) reported no remaining Myriad Genetics position as of Q2 2017 after selling out during the quarter.
  • Beacon Capital Management Inc (Ohio) sold 3 Myriad Genetics shares in Q2 2017.
  • Beacon Capital Management Inc (Ohio) first reported a position in Myriad Genetics in Q1 2017 and held it in 1 quarter.
  • Beacon Capital Management Inc (Ohio)'s Myriad Genetics position peaked at $0 in Q1 2017.
  • 239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Beacon Capital Management Inc (Ohio)'s 13F filing for Q2 2017, filed 11 Jul 2017.